BridgeBio Oncology Therapeutics (BBOT) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- —
- Estimate
- -$0.54
- Surprise
- —
- Score today
- 4.4/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- BridgeBio Oncology Q2 EPS $(705.20) Misses $(0.57) Estimate — benzinga, 2026-08-11
Where TrendMatrix's rating stands now
TrendMatrix currently rates BBOT Hold at 4.4/10; no pre/post engine snapshot brackets this report.
1 of the last 3 quarters beat the estimate. Next scheduled report: 2026-11-11.
What argues against it
- DATA_ISSUE: analyst_target_implausible (raw $24.55 vs price $3.50 — ratio 7.0×). Rejected, falling back to technical TP.
- Market cap $281M below $400M minimum
- Value-trap signals (2/5): Margin compression (op margin -30.9%), Material insider selling (29 sells, 4.00% of cap)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $3.50
- Price target
- $8.68
- Stop
- $3.38
- Upside to target
- +148.0%
Risk check: RSI 20 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-10-07 — shown for context, not personalized investment advice.
BBOT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $280.6M
- P/E (fwd)
- -1.3
- 52-week range
- $3.48–$14.87
- Off 52-week high
- 76.5%
- RSI (14)
- 20
- Volume vs avg
- 0.76×
- Score today
- 4.4/10